Abstract
Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Current Vascular Pharmacology
Title: Targeting Dyslipidemia in the Metabolic Syndrome: An Update
Volume: 8 Issue: 4
Author(s): Kosmas I. Paraskevas, Gabriel Karatzas, Alkisti Pantopoulou, Dimitrios G. Iliopoulos and Despina Perrea
Affiliation:
Keywords: Metabolic syndrome, dyslipidemia, statins, fibrates, ezetimibe, niacin, bile acid sequestrants
Abstract: Background: The management of the Metabolic Syndrome (MetS) includes lifestyle interventions (e.g. diet and exercise for weight reduction), as well as drug treatment to normalize blood pressure, high-density lipoprotein cholesterol, triglycerides and glucose values. Treatment of atherogenic dyslipidemia should comprise a primary therapeutic target since it is associated with an increased risk of cardiovascular disease.
Objective: To review the efficacy of the drugs available for the management of the dyslipidemia associated with MetS.
Methods: MEDLINE was searched up to May 10, 2009 for studies in English using the mesh – terms “metabolic syndrome”, “hypercholesterolemia”, “dyslipidemia”, “treatment”, “statins” and “cardiovascular disease” in various combinations to identify treatment strategies for the management of the dyslipidemia of the MetS.
Results/Conclusions: Several drugs have been described for the management of the dyslipidemia of the MetS, namely statins, fibrates, ezetimibe, niacin, bile acid sequestrants, cholesteryl ester transfer protein inhibitors, as well as combined treatment regimes. Although each of these may deal to some extent with some aspect of the dyslipidemia of the MetS compared with placebo, a direct comparison of all these agents has not been carried out. A head-to-head comparison between the suggested regimes could identify the mono- or combination therapy for the optimal management of dyslipidemia associated with MetS.
Export Options
About this article
Cite this article as:
I. Paraskevas Kosmas, Karatzas Gabriel, Pantopoulou Alkisti, G. Iliopoulos Dimitrios and Perrea Despina, Targeting Dyslipidemia in the Metabolic Syndrome: An Update, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330861
DOI https://dx.doi.org/10.2174/157016110791330861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transfusion-related Acute Lung Injury: An Overview
Current Pharmaceutical Design Synthesis and Antiproliferative Activity of New Polyoxo 2-Benzyl-2,3- dihydrobenzofurans and Their Related Compounds
Letters in Drug Design & Discovery Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets
Current Pharmaceutical Design Editorial (Thematic Issue: Sex, Environment, Physical Activity, Diet, and Obesity in Cardiovascular Disease Risk)
Current Vascular Pharmacology The Developmental Origins of Osteoporosis
Current Genomics Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Noncardiac Surgery: Evaluating and Minimizing Cardiac Risk
Current Cardiology Reviews Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): A Relationship with Implications for Vascular Risk?
Current Vascular Pharmacology Role of Endothelin in Uteroplacental Circulation and Fetal Vascular Function
Current Vascular Pharmacology Editorial [Hot topic:Current Hypertension Reviews, Hot Topics “Obesity, Hypertension, and the Metabolic Syndrome” (Guest Editor: Kazuko Masuo)]
Current Hypertension Reviews Prophylactic Potential of Conventional and Supercritical Garlic Extracts to Alleviate Diet Related Malfunctions
Recent Patents on Food, Nutrition & Agriculture Recent Patents in Plant Biotechnology: Impact on Global Health
Recent Patents on Biotechnology Antithrombotic Therapy for Transcatheter Valvular Interventions: A Revisit
Current Vascular Pharmacology Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Cardiovascular & Hematological Agents in Medicinal Chemistry Roles of Mitogen-Activated Protein Kinases in the Regulation of CYP Genes
Current Drug Metabolism The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued) Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Structural, Biochemical and Non-Traditional Cardiovascular Risk Markers in PCOS
Current Pharmaceutical Design Diagnostic Cardiac Catheterization in the Pediatric Population
Current Cardiology Reviews